Goh Su Kah, Gold Grace, Christophi Christopher, Muralidharan Vijayaragavan
Hepato-Pancreato-Biliary and Transplant Unit, Austin Hospital, Melbourne, Victoria, Australia.
Department of Surgery, The University of Melbourne, Melbourne, Victoria, Australia.
ANZ J Surg. 2017 Dec;87(12):987-992. doi: 10.1111/ans.14131. Epub 2017 Aug 13.
The optimal management of oncological conditions is reflected by the careful interpretation of investigations for screening, diagnosis, staging, prognostication and surveillance. Serum tumour markers are examples of commonly requested tests in conjunction with other imaging and endoscopic tests that are used to help clinicians to stratify therapeutic decisions. Serum carbohydrate antigen 19-9 (CA19-9) is a key biomarker for pancreatic cancers. Although this biomarker is considered clinically useful and informative, clinicians are often challenged by the accurate interpretation of elevated serum CA19-9 levels. Recognizing the pitfalls of normal and abnormal serum CA19-9 concentrations will facilitate its appropriate use. In this review, we appraised the biomarker, serum CA19-9, and highlighted the clinical utility and limitations of serum CA19-9 in the investigation and management of pancreatic cancers.
肿瘤疾病的最佳管理体现在对筛查、诊断、分期、预后评估及监测等检查结果的审慎解读上。血清肿瘤标志物是与其他影像学和内镜检查联合使用的常见检测项目，可帮助临床医生分层制定治疗决策。血清糖类抗原19-9（CA19-9）是胰腺癌的关键生物标志物。尽管该生物标志物在临床上被认为有用且能提供信息，但临床医生常常在准确解读血清CA19-9水平升高方面面临挑战。认识到血清CA19-9浓度正常和异常的陷阱将有助于其合理应用。在本综述中，我们评估了生物标志物血清CA19-9，并强调了血清CA19-9在胰腺癌调查和管理中的临床应用价值及局限性。
